News & Analysis as of

Food and Drug Administration (FDA) Obesity Prescription Drugs

Foley & Lardner LLP

GLP-1 Receptor Agonists: Clinical Trial Considerations

Foley & Lardner LLP on

The U.S. Food & Drug Administration (FDA) has approved certain GLP-1 drugs for commercialization and use, including liraglutide (Victoza®), semaglutide (Ozempic®, Wegovy®), and tirzepatide (Mounjaro®, Zepbound®). Although...more

Patrick Malone & Associates P.C. | DC Injury...

Better Health Care Newsletter - June 2023

Medical experts are rethinking obesity, one of the major harms to Americans’ health. After investigating why heavy patients after bariatric surgeries lose significant weight — and tend to keep it off — researchers have...more

2 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide